DUBLIN--(BUSINESS WIRE)--The "Triple-Negative Breast Cancer KOL Interview - US" report has been added to ResearchAndMarkets.com's offering.
A US-based key opinion leader provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for triple-negative breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed.
Key pipeline assets highlighted include:
- balixafortide
- keytruda
- sacituzumab govitecan
- trastuzumab deruxtecan
- veliparib
For more information about this report visit https://www.researchandmarkets.com/r/d2kmwv
